| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 57
| Issue : 2 | Page : 209-216 |
|
|
Cytokeratin expression in gastrointestinal stromal tumors: Morphology, meaning, and mimicry
Yetish Sing1, Pratistadevi K Ramdial1, Amsha Ramburan1, Vikash Sewram2
1 Department of Anatomical Pathology, School of Laboratory Medicine and Clinical Sciences, University of KwaZulu Natal & National Health Laboratory Service, South Africa
2 Department of Oncology Research Unit, South African Medical Research Council, Durban, KwaZulu-Natal, South Africa
Correspondence Address:
Yetish Sing
Department of Anatomical Pathology, Level 3, Laboratory Building, Inkosi Albert Luthuli Central Hospital, 800 Bellair Road, Mayville, 4058, KwaZulu-Natal
South Africa
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0377-4929.134665
|
|
|
Background: Gastrointestinal stromal tumors (GISTs) are biologically distinctive neoplasms harboring KIT and PDGFRA mutations. Cytokeratin expression in GISTs is an under-recognized diagnostic pitfall, especially in high grade GISTs with limited biopsy material and from metastatic sites. Materials and Methods: We evaluated the histomorphology and expression of four 'broad-spectrum' cytokeratin markers, AE1-AE3, CAM 5.2, MNF-116, and 34βE12 in 64 GISTs diagnosed over a 68-month period. Individual cytokeratins 5, 6, 7, 8, 14, 17, 18, 19, and 20 were investigated in the 'broad-spectrum' cytokeratin-positive GISTs. Results: Of 64 GISTs, 10 (15%) demonstrated cytokeratin immunopositivity. All 10, considered high risk by the National Institutes of Health consensus approach, were immunopositive for CAM 5.2 and MNF-116. Seven were AE1-AE3 immunopositive. Cytokeratins 8 and 18 were confirmed in 10 and 9 GISTs, respectively. One GIST demonstrated biphasic morphology with cytokeratin immunonegativity in low-grade spindle and immunopositivity in high-grade epithelioid foci. KIT and PDGFRA mutational analysis, undertaken in 5/10 cytokeratin-positive GISTs, harbored KIT exon 11 mutations. Conclusion: We hypothesize that cytokeratin expression exclusively in high risk GISTs is a consequence of tumor progression. Given the increasing number of commercially available broad-spectrum cytokeratin immunomarkers, including those reacting with cytokeratins 8 and 18, cytokeratin-positive GISTs must be differentiated from carcinomas, melanomas, and a range of cytokeratin-positive sarcomas to ensure optimal patient management and prognostication. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
